Side effects include skin rash and diarrhea ... You may take cemiplimab (Libtayo), nivolumab (Opdivo), or pembrolizumab (Keytruda). Atezolizumab (Tecentriq) and durvalumab (Imfinzi) may also ...

The drug could also have a unique selling point in this indication as results from the phase 3 trial came from Libtayo monotherapy ... who cannot tolerate the side effects.

Sanofi’s cancer immunotherapy Libtayo (cemiplimab) has a third US indication after the FDA approved it for certain untreated lung cancer patients. The approval in first-line lung cancer ...